Top Markets
#1 Resolv wstUSR Resolv wstUSR +114.56%
#2 Luxxcoin Luxxcoin +46.85%
#3 Layer3 Layer3 +32.82%
#4 ResearchCoin ResearchCoin +31.78%
#5 Reactive Network Reactive Network +24.01%
#6 Orderly Network Orderly Network +17.27%
#7 Bitgert Bitgert +17.01%
#8 Lisk Bridged wstETH (Lisk) Lisk Bridged wstETH (Lisk) +10.20%
#9 Useless Coin Useless Coin +10.11%
#10 OpenVPP OpenVPP +9.68%
Coin of the day
Resolv wstUSR Resolv wstUSR
Settings
Language
ENGLISH
Currency
USD
Theme
CSL Limited CSL Limited

CSL Limited

CSL
Rank in Stocks #432
CSL Limited researches, develops, manufactures, markets, and distributes... CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Share Price
$99.32
Market Cap
$48.20B
Change (1 day)
0.98%
Change (1 year)
-32.14%
Country
AU
Trade CSL Limited (CSL)

Category

Healthcare
P/E ratio for CSL Limited (CSL)
P/E ratio as of April 2026 TTM: 33.03
According to CSL Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 33.03. At the end of 2024 the company had a P/E ratio of 35.62.
P/E ratio history for CSL Limited from 2000 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) 33.03 30.02%
2025 25.40 -28.71%
2024 35.62 -12.19%
2023 40.57 5.09%
2022 38.60 -5.12%
2021 40.69 -32.11%
2020 59.93 68.35%
2019 35.60 -29.76%
2018 50.68 7.85%
2017 46.99 51.20%
2016 31.08 36.38%
2015 22.79 -7.49%
2014 24.64 -0.91%
2013 24.86 19.28%
2012 20.84 9.38%
2011 19.06 9.86%
2010 17.35 3.98%
2009 16.68 -42.96%
2008 29.25 -1.80%
2007 29.78 -64.33%
2006 83.49 590.62%
2005 12.09 -53.26%
2004 25.86 -5.79%
2003 27.45 -61.19%
2002 70.73 -22.63%
2001 91.43 12.86%
2000 81.01 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 10.02 -69.67%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.68 -13.16%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 17.65 -46.56%
US
UCB SA UCB SA
UCB SA
UCB.BR
 31.52 -4.55%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 39.06 18.28%
NL
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.